Risperdal Consta Approved for Bipolar Disorder

May 18 (HealthDay News) -- The Janssen Pharmaceuticals drug Risperdal Consta (risperidone) has been approved by the U.S. Food and Drug Administration for people with Bipolar 1 disorder, the drug maker said Monday.

Risperdal Consta is the long-acting version of Risperdal, which was first FDA-approved more than a decade ago and is now sanctioned for Bipolar 1, schizophrenia and autism.

Type 1 bipolar disorder involves at least one manic episode, with or without a major depressive episode.

Approval of Risperdal Consta for Bipolar 1 was granted as a single therapy, or in combination with lithium or valproate, Janssen said in a news release.

As with similar antipsychotic drugs, the packaging for Risperdal Consta includes a warning that the drug is not approved for elderly people with dementia-related psychosis, and could increase their risk of death.


Like this? Want more?
preview
Connect with Us
Follow Our Pins

Yummy recipes, DIY projects, home decor, fashion and more curated by iVillage staffers.

Follow Our Tweets

The very dirty truth about fashion internships... DUN DUN @srslytheshow http://t.co/wfewf

On Instagram

Behind-the-scenes pics from iVillage.

Best of the Web